AVPR2 and type 2 diabetes mellitus: Some of the few medicines on the market with HPC are Samsca® (API Tolvaptan is a selective vasopressin V2-receptor antagonist), available since 2018 under FDA approval, and Eucreas® GalvumetTM (API Vildagliptin/Metformin HCL) for the therapy of type II diabetes, manufactured by Novartis since 2007 under EMA approval [12,47].